Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Vireo Growth Inc
Vireo Growth Inc. Announces Third Quarter 2025 Results
Business
Nov 12 2025
21 min read

Vireo Growth Inc. Announces Third Quarter 2025 Results

news images

Q3 GAAP revenue of $91.7 million increased 264% year-over-year, driven by recently closed M&A transactions and organic growth throughout the portfolio

Completed refinancing of senior secured debt which is expected to decrease annualized interest expense by $10 million

Closed Q3 with $117 million in cash; expects to remain acquisitive in distressed environment

MINNEAPOLIS, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today reported financial results for its third fiscal quarter ended September 30, 2025. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance. All currency figures referenced herein are denominated in U.S. dollars.

Summary of Key Financial Metrics

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

US $in millions

 

September 30,

 

September 30,

 

 

 

2025

 

2024

 

Variance

 

2025

 

2024

 

Variance

 

GAAP Revenue

 

$

91.7

 

$

25.2

 

264.2

%

$

164.3

 

$

74.4

 

120.9

%

GAAP Gross Profit

 

$

37.4

 

$

12.3

 

204.1

%

$

70.2

 

$

38.1

 

84.3

%

Gross Profit Margin

 

 

40.8

%

 

49.0

%

-820

bps

 

42.7

%

 

51.3

%

-860

bps

Adjusted Gross Profit1

 

$

50.8

 

$

12.7

 

300.0

%

$

88.5

 

$

38.2

 

131.7

%

Adjusted Gross Profit Margin1

 

 

55.4

%

 

50.4

%

500

bps

 

53.9

%

 

51.3

%

250

bps

GAAP Operating Income

 

$

0.8

 

$

3.9

 

-79.0

%

$

0.8

 

$

14.4

 

-94.7

%

GAAP Operating Income Margin

 

 

0.9

%

 

15.5

%

-1,460

bps

 

0.5

%

 

19.4

%

-1,890

bps

Adjusted Operating Income2

 

$

21.0

 

$

5.2

 

303.8

%

$

38.0

 

$

15.8

 

140.5

%

Adjusted Operating Income Margin2

 

 

22.9

%

 

20.6

%

230

bps

 

23.1

%

 

21.2

%

190

bps

Adjusted EBITDA

 

$

25.4

 

$

6.4

 

297.0

%

$

45.2

 

$

18.5

 

144.7

%

Adjusted EBITDA Margin

 

 

27.7

%

 

25.3

%

230

bps

 

27.5

%

 

24.8

%

268

bps

1Excludes fair value adjustments and Grown Rogue termination fee
2Excludes fair value adjustments, Grown Rogue termination fee, share based compensation and transaction expenses
NOTE: Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income, Adjusted Operating Income Margin, Adjusted EBITDA, and Adjusted EBITDA Margin are non-GAAP financial measures. Please refer to the end of this press release for a definition of these measures and a reconciliation to the most directly comparable GAAP measures.

Management Commentary

Chief Executive Officer John Mazarakis commented, “Our third quarter results reflect continued progress against our objective to create a portfolio of prolific brands in cannabis. Performance was in line with our expectations and is beginning to demonstrate the impact of our efforts to transform the Company through accretive M&A. As we exit 2025 and begin the new year, we will continue optimizing all areas of our business while remaining opportunistic with respect to further acquisitive growth opportunities.”

Recent Developments

On September 16, 2025, the Company recorded its first sale of adult use cannabis in Minnesota at its historic downtown Minneapolis Green Goods® dispensary. The Company is now dispensing a full suite of both medical and adult-use cannabis products at all eight of its Green Goods™ dispensaries located throughout the State of Minnesota. As one of the state’s operational licensed adult-use cannabis cultivators and retailers, and with a population of 5.7 million people, the launch of Minnesota’s adult-use cannabis market is expected to serve as an organic revenue growth catalyst for Vireo for the foreseeable future.

On October 14, 2025, the Company announced that it closed on a transaction to acquire outstanding senior secured convertible notes of public U.S. multi-state cannabis operator Schwazze, and that it entered into a Restructuring Support Agreement with Schwazze. The parties plan to restructure the operations and capital structure of Schwazze and its subsidiaries through a series of transactions, including the UCC sale of certain assets representing a majority of the total assets of Schwazze to a newly-formed entity to be majority-owned by Vireo, and the liquidation and winding down of Schwazze’s remaining operations. Schwazze currently operates 46 dispensaries and 2 manufacturing facilities throughout Colorado and New Mexico.

On October 29, 2025, the Company announced that it has reached a comprehensive settlement agreement with Verano Holdings Corp., dismissing all outstanding litigation matters between the two companies that are pending before the Supreme Court of British Columbia, Canada. The terms of the agreement were approved by the respective Boards of Directors of both companies. The value of the settlement to Vireo is approximately $10 million.

At the end of the third quarter, the Company had largely completed integration of its recent acquisitions, including streamlined accounting, finance, human resources, insurance, and procurement operations, as well as the implementation of a new Enterprise Resource Planning system across the organization. The Company has already realized corporate overhead synergies, and full integration is expected to be completed by the end of the year.

Balance Sheet and Liquidity

As of September 30, 2025, total current assets excluding New York assets held for sale and income taxes receivable were $191.1 million, including cash on hand of $117.5 million. Total current liabilities excluding New York liabilities held for sale and uncertain tax liabilities were $60.8 million. As of September 30, 2025, the Company had a total of 1,062,254,684 shares outstanding on the treasury method basis using a share price of $0.64.

Conference Call and Webcast Information

Vireo management will host a conference call with research analysts today, November 12, 2025, at 8:30 a.m. ET (7:30 a.m. CT) to discuss its financial results for its third quarter ended September 30, 2025. Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 7974705.

A live audio webcast of this event will also be available in the Events & Presentations section of the Company’s Investor Relations website and via the following link:
https://events.q4inc.com/attendee/235390523.

About Vireo Growth Inc.

Vireo was founded in 2014 as a pioneering medical cannabis company. Vireo is building a disciplined, strategically aligned, and execution-focused platform in the industry. This strategy drives our intense local market focus while leveraging the strength of a national portfolio. We are committed to hiring industry leaders and deploying capital and talent where we believe it will drive the most value. Vireo operates with a long-term mindset, a bias for action, and an unapologetic commitment to its customers, employees, shareholders, industry collaborators, and the communities it serves. For more information about Vireo, visit www.vireogrowth.com.

Additional Information

Additional information relating to the Company’s third quarter 2025 results will be available on EDGAR and SEDAR+ later today. Vireo refers to certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income, and Adjusted Operating Income Margin in circumstances in which the Company believes that doing so provides additional perspective and insights when analyzing the core operating performance of the business. These measures do not have any standardized meaning and may not be comparable to similar measures presented by other issuers. Please see the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this news release for more detailed information regarding non-GAAP financial measures including a reconciliation of each measure to the most directly comparable GAAP financial measure.

Contact Information

Joe Duxbury
Chief Accounting Officer
investor@vireogrowth.com 
(612) 314-8995

Forward-Looking Statement Disclosure

This press release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes “financial outlooks” within the meaning of applicable United States or Canadian securities laws, this information is being provided as preliminary financial results; the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” and variations of such words and phrases, or any statements or clauses containing verbs in any future tense and includes statements regarding the expected decrease in annualized interest expense as a result of the completion of the refinancing of senior secured debt; the Company’s future M&A strategy and optimization of all areas of the Company’s business; the expected benefits of the Company’s expansion into the adult-use cannabis market, including expected future revenues and growth associated therewith; expectations around the proposed transactions involving Schwazze and its assets; and the Company’s expectations around integration of the operations of its recent acquisitions at timing thereof. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks

as set out herein and in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q filed with the Securities Exchange Commission. Our actual financial position and results of operations may differ materially from management’s current expectations and, as a result, our revenue, EBITDA, Adjusted EBITDA, and cash on hand may differ materially from the values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to meet the demand for flower in its various markets; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.com.

The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.


VIREO GROWTH INC.
STATE-BY-STATE REVENUE PERFORMANCE
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

 

2025

 

2024

 

$Change

 

% Change

 

Retail:

 

 

 

 

 

 

 

 

 

 

 

 

MN

 

$

11,954,050

 

$

11,391,969

 

$

562,081

 

 

5

%

NY

 

 

985,914

 

 

1,428,827

 

 

(442,913)

 

 

(31)

%

MD

 

 

6,620,115

 

 

6,919,991

 

 

(299,876)

 

 

(4)

%

UT

 

 

11,476,957

 

 

 

 

11,476,957

 

 

100

%

NV

 

 

24,946,810

 

 

 

 

24,946,810

 

 

100

%

MO

 

 

19,968,137

 

 

 

 

19,968,137

 

 

100

%

Total Retail

 

$

75,951,983

 

$

19,740,787

 

$

56,211,196

 

 

285

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Wholesale:

 

 

 

 

 

 

 

 

 

 

 

 

MN

 

$

66,812

 

 

146,461

 

 

(79,649)

 

 

(54)

%

NY

 

 

5,117,153

 

 

1,321,224

 

 

3,795,929

 

 

287

%

MD

 

 

3,749,186

 

 

3,956,871

 

 

(207,685)

 

 

(5)

%

UT

 

 

1,856,967

 

 

 

 

1,856,967

 

 

100

%

NV

 

 

24,244

 

 

 

 

24,244

 

 

100

%

MO

 

 

4,888,810

 

 

 

 

4,888,810

 

 

100

%

Total Wholesale

 

$

15,703,172

 

$

5,424,556

 

$

10,278,616

 

 

189

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenue

 

$

91,655,155

 

$

25,165,343

 

$

66,489,812

 

 

264

%


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

 

2025

 

2024

 

$Change

 

% Change

 

Retail:

 

 

 

 

 

 

 

 

 

 

 

 

MN

 

$

34,021,309

 

$

34,608,015

 

$

(586,706)

 

 

(2)

%

NY

 

 

3,285,510

 

 

4,854,423

 

 

(1,568,913)

 

 

(32)

%

MD

 

 

20,189,092

 

 

20,696,808

 

 

(507,716)

 

 

(2)

%

UT

 

 

17,578,578

 

 

 

 

17,578,578

 

 

100

%

NV

 

 

31,308,095

 

 

 

 

31,308,095

 

 

100

%

MO

 

 

25,575,600

 

 

 

 

25,575,600

 

 

100

%

Total Retail

 

$

131,958,184

 

$

60,159,246

 

$

71,798,938

 

 

119

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Wholesale:

 

 

 

 

 

 

 

 

 

 

 

 

MN

 

 

507,936

 

 

153,330

 

 

354,606

 

 

231

%

NY

 

 

10,181,207

 

 

3,454,162

 

 

6,727,045

 

 

195

%

MD

 

 

12,021,131

 

 

10,594,167

 

 

1,426,964

 

 

13

%

UT

 

 

2,963,723

 

 

 

 

2,963,723

 

 

100

%

NV

 

 

52,450

 

 

 

 

52,450

 

 

100

%

MO

 

 

6,574,175

 

 

 

 

6,574,175

 

 

100

%

Total Wholesale

 

$

32,300,622

 

$

14,201,659

 

$

18,098,963

 

 

127

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenue

 

$

164,258,806

 

$

74,360,905

 

$

89,897,901

 

 

121

%


Supplemental Information and Reconciliation of Non-GAAP Financial Measures

Vireo management occasionally elects to provide certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income, and Adjusted Operating Income Margin. EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income, and Adjusted Operating Income Margin are non-GAAP measures and do not have standardized definitions under GAAP. The following information provides reconciliations of the supplemental non-GAAP financial measures presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.

Reconciliation of Net Loss to EBITDA and Adjusted EBITDA

We have included this information as management believes certain investors use this information to evaluate our performance in comparison to other cannabis companies. The table below provides a reconciliation of net loss to EBITDA and to Adjusted EBITDA.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

Three Months Ended

    

Nine Months Ended

 

 

September 30,

 

September 30,

 

 

2025

    

2024

 

2025

    

2024

Net income (loss)

 

$

(26,298,861

)

 

$

(4,926,358

)

 

$

(47,741,680

)

 

$

(12,306,228

)

Interest expense, net

 

 

6,906,226

 

 

 

7,363,655

 

 

 

22,153,565

 

 

 

23,604,746

 

Income taxes

 

 

13,347,000

 

 

 

2,385,000

 

 

 

19,876,000

 

 

 

6,770,000

 

Depreciation & Amortization

 

 

2,082,819

 

 

 

256,326

 

 

 

3,441,872

 

 

 

762,864

 

Depreciation and amortization included in cost of sales

 

 

1,813,459

 

 

 

582,072

 

 

 

3,242,131

 

 

 

1,752,770

 

EBITDA (non-GAAP)

 

$

(2,149,357

)

 

$

5,660,695

 

 

$

971,888

 

 

$

20,584,152

 

Non-cash inventory adjustments

 

 

13,394,126

 

 

 

393,000

 

 

 

17,753,085

 

 

 

130,000

 

Grown Rogue termination fee included in cost of goods sold

 

 

 

 

 

 

 

 

533,333

 

 

 

 

Stock-based compensation

 

 

4,006,712

 

 

 

1,304,919

 

 

 

9,618,192

 

 

 

1,424,140

 

Transaction related expenses

 

 

803,724

 

 

 

 

 

 

6,777,864

 

 

 

 

Other income

 

 

(479,245

)

 

 

(970,850

)

 

 

(861,610

)

 

 

(3,881,931

)

Debt financing costs

 

 

1,873,589

 

 

 

 

 

 

1,873,589

 

 

 

 

Severance expense

 

 

74,320

 

 

 

 

 

 

694,159

 

 

 

 

Loss on disposal of assets

 

 

7,837,671

 

 

 

 

 

 

7,843,515

 

 

 

218,327

 

Adjusted EBITDA (non-GAAP)

 

$

25,361,541

 

 

$

6,387,764

 

 

$

45,204,016

 

 

$

18,474,688

 


The financial information reported in this news release is based on unaudited financial statements for the third quarter ended September 30, 2025, and September 30, 2024. All financial information contained in this news release is qualified in its entirety with reference to such financial statements. To the extent that the financial information contained in this news release is inconsistent with the information contained in the Company’s audited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company’s audited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

Reconciliation of Q3 Gross Profit to Adjusted Gross Profit

The table below provides a reconciliation of Gross Profit to Adjusted Gross Profit. Adjusted Gross Profit Margin represents Adjusted Gross Profit divided by GAAP revenue for the relevant period.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

 

 

2025

 

2024

 

2025

 

2024

 

Gross Profit

 

$

37,382,999

 

$

12,323,970

 

$

70,213,158

 

$

38,119,040

 

Non-cash inventory adjustments

 

 

13,394,126

 

 

393,000

 

 

17,753,085

 

 

130,000

 

Grown Rogue termination fee included in cost of goods sold

 

 

 

 

 

 

533,333

 

 

 

Adjusted Gross Profit (non-GAAP)

 

$

50,777,125

 

$

12,716,970

 

$

88,499,576

 

$

38,249,040

 


Reconciliation of Q3 Operating Income to Adjusted Operating Income

The table below provides a reconciliation of Gross Profit to Adjusted Gross Profit. Adjusted Operating Income Margin represents Adjusted Operating Income divided by GAAP revenue for the relevant period.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

Three Months Ended

    

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

 

 

2025

    

2024

 

2025

    

2024

 

Operating Income

 

$

808,956

 

$

3,851,447

 

$

765,955

 

$

14,404,914

 

Non-cash inventory adjustments

 

 

13,394,126

 

 

 

 

17,753,085

 

 

 

Grown Rogue termination fee included in cost of goods sold

 

 

 

 

 

 

533,333

 

 

 

Stock-based compensation

 

 

4,006,712

 

 

1,304,919

 

 

9,618,192

 

 

1,424,140

 

Debt financing costs

 

 

1,873,589

 

 

 

 

1,873,589

 

 

 

Severance expense

 

 

74,320

 

 

 

 

694,159

 

 

 

Transaction related expenses

 

 

803,724

 

 

 

 

6,777,864

 

 

 

Adjusted Operating Income (non-GAAP)

 

$

20,961,427

 

$

5,156,366

 

$

38,016,177

 

$

15,829,054

 



VIREO GROWTH INC.
CONSOLIDATED BALANCE SHEETS AS OF 9/30/2025 AND 12/31/2024
(Amounts Expressed in United States Dollars, Unaudited and Condensed)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

December 31,

 

 

 

2025

 

2024

 

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash

 

$

97,151,669

 

 

$

91,604,970

 

 

Restricted Cash

 

 

20,387,672

 

 

 

 

 

Marketable Securities

 

 

1,012,527

 

 

 

 

 

Accounts receivable, net of credit losses of $1,027,316 and $244,264, respectively

 

 

12,180,295

 

 

 

4,590,351

 

 

Income tax receivable

 

 

14,414,476

 

 

 

12,027,472

 

 

Inventory

 

 

53,901,588

 

 

 

21,666,364

 

 

Prepayments and other current assets

 

 

5,114,818

 

 

 

1,650,977

 

 

Warrants held

 

 

1,333,103

 

 

 

2,270,964

 

 

Assets Held for Sale

 

 

102,468,441

 

 

 

96,560,052

 

 

Total current assets

 

 

307,964,589

 

 

 

230,371,150

 

 

Property and equipment, net

 

 

121,241,954

 

 

 

32,311,762

 

 

Operating lease, right-of-use asset

 

 

37,112,753

 

 

 

7,859,434

 

 

Intangible assets, net

 

 

89,651,531

 

 

 

7,899,328

 

 

Goodwill

 

 

97,289,115

 

 

 

 

 

Investments

 

 

6,000,000

 

 

 

 

 

Deposits

 

 

2,129,430

 

 

 

421,244

 

 

Indemnified Assets

 

 

17,529,137

 

 

 

 

 

Total assets

 

 

678,918,509

 

 

$

278,862,918

 

 

Liabilities

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

 

38,543,289

 

 

$

10,456,036

 

 

Convertible debt, current portion

 

$

1,650,000

 

 

 

 

 

Long-Term debt, current portion

 

 

15,630,000

 

 

 

900,000

 

 

Right of use liability

 

 

4,771,482

 

 

 

1,400,015

 

 

Uncertain tax liability

 

 

84,818,307

 

 

 

33,324,000

 

 

Derivative Liability

 

 

160,778

 

 

 

 

 

Liabilities held for sale

 

 

89,334,872

 

 

 

89,387,203

 

 

Total current liabilities

 

 

234,908,728

 

 

 

135,467,254

 

 

Right-of-use liability

 

 

41,772,546

 

 

 

16,494,439

 

 

Long-term debt, net

 

 

131,665,305

 

 

 

61,438,046

 

 

Convertible debt, net

 

 

8,246,109

 

 

 

9,862,378

 

 

Contingent consideration

 

 

14,919,000

 

 

 

 

 

Other long-term liabilities

 

 

1,101,299

 

 

 

37,278

 

 

Total liabilities

 

 

432,612,987

 

 

 

223,299,395

 

 

Stockholders’ equity

 

 

 

 

 

 

 

Subordinate Voting Shares ($- par value, unlimited shares authorized; 923,898,809 shares issued and outstanding at September 30, 2025 and 337,512,681 at December 31, 2024)

 

 

 

 

 

 

 

Multiple Voting Shares ($- par value, unlimited shares authorized; 259,632 shares issued and outstanding at September 30, 2025 and 285,371 at December 31, 2024)

 

 

 

 

 

 

 

Additional paid in capital

 

 

525,482,763

 

 

 

286,999,084

 

 

Accumulated deficit

 

 

(279,177,241

)

 

 

(231,435,561

)

 

Total stockholders’ equity

 

$

246,305,522

 

 

$

55,563,523

 

 

Total liabilities and stockholders’ equity

 

$

678,918,509

 

 

$

278,862,918

 

 



VIREO GROWTH INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Amounts Expressed in United States Dollars, Unaudited and Condensed)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

 

    

2025

    

2024

    

2025

    

2024

 

Revenue

 

$

91,655,155

 

 

$

25,165,343

 

 

$

164,258,806

 

 

$

74,360,905

 

 

Cost of sales

 

 

 

 

 

 

 

 

 

 

 

 

 

Product costs

 

 

40,878,030

 

 

 

12,448,373

 

 

 

76,292,563

 

 

 

36,111,865

 

 

Non-cash product costs

 

 

12,397,641

 

 

 

 

 

 

16,549,749

 

 

 

 

 

Inventory valuation adjustments

 

 

996,485

 

 

 

393,000

 

 

 

1,203,336

 

 

 

130,000

 

 

Gross profit

 

 

37,382,999

 

 

 

12,323,970

 

 

 

70,213,158

 

 

 

38,119,040

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

29,680,788

 

 

 

6,911,278

 

 

 

49,609,275

 

 

 

21,527,122

 

 

Transaction related expenses

 

 

803,724

 

 

 

 

 

 

6,777,864

 

 

 

 

 

Stock-based compensation expenses

 

 

4,006,712

 

 

 

1,304,919

 

 

 

9,618,192

 

 

 

1,424,140

 

 

Depreciation

 

 

552,589

 

 

 

76,292

 

 

 

1,017,287

 

 

 

222,763

 

 

Amortization

 

 

1,530,230

 

 

 

180,034

 

 

 

2,424,585

 

 

 

540,101

 

 

Total operating expenses

 

 

36,574,043

 

 

 

8,472,523

 

 

 

69,447,203

 

 

 

23,714,126

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain (loss) from operations

 

 

808,956

 

 

 

3,851,447

 

 

 

765,955

 

 

 

14,404,914

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expenses, net

 

 

(6,906,226

)

 

 

(7,363,655

)

 

 

(22,153,565

)

 

 

(23,604,746

)

 

Gain (loss) on disposal of assets

 

 

(7,837,671

)

 

 

 

 

 

(7,843,515

)

 

 

(218,327

)

 

Other income (expenses)

 

 

983,080

 

 

 

970,850

 

 

 

1,365,445

 

 

 

3,881,931

 

 

Other income (expenses), net

 

 

(13,760,817

)

 

 

(6,392,805

)

 

 

(28,631,635

)

 

 

(19,941,142

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

 

(12,951,861

)

 

 

(2,541,358

)

 

 

(27,865,680

)

 

 

(5,536,228

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current income tax expenses

 

 

(13,347,000

)

 

 

(2,385,000

)

 

 

(19,876,000

)

 

 

(6,770,000

)

 

Net loss and comprehensive loss

 

 

(26,298,861

)

 

 

(4,926,358

)

 

 

(47,741,680

)

 

 

(12,306,228

)

 

Net loss per share - basic and diluted

 

$

(0.04

)

 

$

(0.02

)

 

$

(0.05

)

 

$

(0.08

)

 

Weighted average shares used in computation of net loss per share - basic & diluted

 

 

627,654,382

 

 

 

201,377,275

 

 

 

949,820,535

 

 

 

162,836,874

 

 



VIREO GROWTH INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Amounts Expressed in United States Dollars, Unaudited and Condensed)

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30,

 

 

    

2025

    

2024

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

 

Net loss

 

$

(47,741,680

)

 

$

(12,306,228

)

 

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

Non-cash amortization of inventory step up included in product costs

 

 

16,549,749

 

 

 

 

 

Inventory valuation adjustments

 

 

1,203,336

 

 

 

130,000

 

 

Depreciation

 

 

1,017,287

 

 

 

222,763

 

 

Depreciation capitalized into inventory

 

 

3,177,308

 

 

 

1,678,434

 

 

Non-cash operating lease expense

 

 

1,093,085

 

 

 

323,309

 

 

Amortization of intangible assets

 

 

2,424,585

 

 

 

540,101

 

 

Amortization of intangible assets capitalized into inventory

 

 

64,823

 

 

 

74,336

 

 

Stock-based payments

 

 

9,461,855

 

 

 

1,424,140

 

 

Warrants held

 

 

937,861

 

 

 

(3,284,619

)

 

Derivative (gain) loss

 

 

160,778

 

 

 

 

 

Loss on extinguishment of debt

 

 

4,911,988

 

 

 

 

 

Interest Expense

 

 

3,074,234

 

 

 

3,806,093

 

 

Bad debt expense

 

 

313,618

 

 

 

230,818

 

 

Accretion of interest on right-of-use finance lease liabilities

 

 

160,392

 

 

 

168,464

 

 

Loss (gain) on disposal of assets

 

 

(863,813

)

 

 

120,856

 

 

Change in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts Receivable

 

 

(4,192,453

)

 

 

173,047

 

 

Prepaid expenses

 

 

(953,498

)

 

 

(496,757

)

 

Inventory

 

 

(2,396,728

)

 

 

(482,192

)

 

Income taxes

 

 

8,832,232

 

 

 

361,154

 

 

Uncertain tax position liabilities

 

 

14,411,000

 

 

 

6,410,000

 

 

Accounts payable and accrued liabilities

 

 

(18,800,446

)

 

 

1,213,360

 

 

Changes in operating lease liabilities

 

 

(1,829,045

)

 

 

(404,556

)

 

Change in assets and liabilities held for sale

 

 

(5,960,720

)

 

 

(3,693,771

)

 

Net cash used in operating activities

 

 

(14,944,252

)

 

 

(3,791,248

)

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

Purchases of property, plant, and equipment

 

 

(18,461,912

)

 

 

(8,974,901

)

 

Proceeds from note receivable

 

 

 

 

 

3,600,000

 

 

Purchase of marketable securities

 

 

(1,012,527

)

 

 

 

 

Acquisition of WholesomeCo, Inc., net of cash paid

 

 

7,025,811

 

 

 

 

 

Acquisition of Deep Roots Holdings, Inc., net of cash paid

 

 

19,382,607

 

 

 

 

 

Acquisition of Proper Holdings Management, Inc., net of cash paid

 

 

12,951,202

 

 

 

 

 

Capitalized software development costs

 

 

(1,065,611

)

 

 

 

 

Deposits

 

 

(638,262

)

 

 

(150,100

)

 

Net cash used in investing activities

 

 

18,181,308

 

 

 

(5,525,001

)

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

Proceeds from long-term debt, net of issuance costs

 

 

146,789,514

 

 

 

1,131,400

 

 

Proceeds from issuance of shares

 

 

 

 

 

700,000

 

 

Proceeds from warrant exercises

 

 

38,516

 

 

 

43,953

 

 

Proceeds from option exercises

 

 

90,890

 

 

 

16,500

 

 

Debt principal payments

 

 

(124,221,605

)

 

 

(1,098,000

)

 

Lease principal payments

 

 

 

 

 

(162,405

)

 

Net cash used in financing activities

 

 

22,697,315

 

 

 

631,448

 

 

Net change in cash

 

 

25,934,371

 

 

 

(8,684,801

)

 

Cash, beginning of period

 

 

91,604,970

 

 

 

15,964,665

 

 

Cash, end of period

 

$

117,539,341

 

 

$

7,279,864